ClinicalTrials.gov
ClinicalTrials.gov Menu

Electronic Study for Anastrozole Pharmacovigilance Evaluation (E-SAFE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00558168
Recruitment Status : Completed
First Posted : November 14, 2007
Last Update Posted : July 28, 2008
Sponsor:
Information provided by:
AstraZeneca

Brief Summary:
Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer

Condition or disease
Early Breast Cancer

Study Type : Observational
Actual Enrollment : 1850 participants
Time Perspective: Prospective
Official Title: Electronic Study for Anastrozole Pharmacovigilance Evaluation
Study Start Date : January 2004
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Anastrozole





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Post-menopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions.

Exclusion Criteria:

  • Metastatic breast cancer patients, previous hormonal therapy, other malignancies.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00558168


Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Nejdet Uskent Kadir Has University Medical School

ClinicalTrials.gov Identifier: NCT00558168     History of Changes
Other Study ID Numbers: ARI-IPEP-0104
First Posted: November 14, 2007    Key Record Dates
Last Update Posted: July 28, 2008
Last Verified: July 2008

Keywords provided by AstraZeneca:
Anastrazole
safety
early breast cancer

Additional relevant MeSH terms:
Anastrozole
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs